Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy

Artemios K. Artemiadis, Irene Lambrinoudaki, Panagiota Voskou, Georgios Tsivgoulis, Apostolos Safouris, Anastasia Bougea, Sotiris Giannopoulos, Stergios Gatzonis, Nikolaos Triantafyllou

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Enzyme-inducing antiepileptic drugs AEDs have adverse effects on bone mineral density (BMD), whereas studies on levetiracetam (LEV), a nonenzyme-inducing agent, have showed conflicting results. The aim of this study was to further elucidate the role of LEV in bone health. A sample of forty-six patients with epilepsy (mean age: 35.7 years, range: 20.2-64.2 years, 39.1% males) on LEV monotherapy for at least one year (range: 1.5-14.5 years, median 5.5 years) underwent femoral neck (FN) and lumbar spine (LS) BMD measurements. The T- and Z-scores were calculated. Results showed that 15.2% of the patients were identified with osteopenia and none with osteoporosis. Pearson's correlations revealed a negative but not significant association of LEV duration with bone-related measurements (range of rhos: from - 0.004 to - 0.23), except for LS T-scores. In terms of FN BMD measurements, Z-scores, and T-scores, longer LEV therapy duration had adverse but not significant effects on bone health after adjusting for age and gender. With regard to LS BMD measurements, Z-scores, and T-scores, men taking LEV for at least 5.5 years had better, although not significant, bone health compared with men with shorter LEV exposure, after adjusting for age. The opposite was found in women, although differences did not reach significance. These preliminary results are indicative of a differential effect of LEV therapy duration in men and women, which could presumably account for the incongruity of the already published studies. Also, LS assessments were more sensitive to these gender differences. Future larger studies should validate these results.

Original languageEnglish (US)
Pages (from-to)84-86
Number of pages3
JournalEpilepsy and Behavior
Volume55
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

etiracetam
Epilepsy
Bone and Bones
Health
Bone Density
Spine
Femur Neck
Metabolic Bone Diseases

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. / Artemiadis, Artemios K.; Lambrinoudaki, Irene; Voskou, Panagiota; Tsivgoulis, Georgios; Safouris, Apostolos; Bougea, Anastasia; Giannopoulos, Sotiris; Gatzonis, Stergios; Triantafyllou, Nikolaos.

In: Epilepsy and Behavior, Vol. 55, 01.02.2016, p. 84-86.

Research output: Contribution to journalArticle

Artemiadis, AK, Lambrinoudaki, I, Voskou, P, Tsivgoulis, G, Safouris, A, Bougea, A, Giannopoulos, S, Gatzonis, S & Triantafyllou, N 2016, 'Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy', Epilepsy and Behavior, vol. 55, pp. 84-86. https://doi.org/10.1016/j.yebeh.2015.12.025
Artemiadis, Artemios K. ; Lambrinoudaki, Irene ; Voskou, Panagiota ; Tsivgoulis, Georgios ; Safouris, Apostolos ; Bougea, Anastasia ; Giannopoulos, Sotiris ; Gatzonis, Stergios ; Triantafyllou, Nikolaos. / Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. In: Epilepsy and Behavior. 2016 ; Vol. 55. pp. 84-86.
@article{f6a4588d8dfd418196373af5331dea41,
title = "Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy",
abstract = "Enzyme-inducing antiepileptic drugs AEDs have adverse effects on bone mineral density (BMD), whereas studies on levetiracetam (LEV), a nonenzyme-inducing agent, have showed conflicting results. The aim of this study was to further elucidate the role of LEV in bone health. A sample of forty-six patients with epilepsy (mean age: 35.7 years, range: 20.2-64.2 years, 39.1{\%} males) on LEV monotherapy for at least one year (range: 1.5-14.5 years, median 5.5 years) underwent femoral neck (FN) and lumbar spine (LS) BMD measurements. The T- and Z-scores were calculated. Results showed that 15.2{\%} of the patients were identified with osteopenia and none with osteoporosis. Pearson's correlations revealed a negative but not significant association of LEV duration with bone-related measurements (range of rhos: from - 0.004 to - 0.23), except for LS T-scores. In terms of FN BMD measurements, Z-scores, and T-scores, longer LEV therapy duration had adverse but not significant effects on bone health after adjusting for age and gender. With regard to LS BMD measurements, Z-scores, and T-scores, men taking LEV for at least 5.5 years had better, although not significant, bone health compared with men with shorter LEV exposure, after adjusting for age. The opposite was found in women, although differences did not reach significance. These preliminary results are indicative of a differential effect of LEV therapy duration in men and women, which could presumably account for the incongruity of the already published studies. Also, LS assessments were more sensitive to these gender differences. Future larger studies should validate these results.",
author = "Artemiadis, {Artemios K.} and Irene Lambrinoudaki and Panagiota Voskou and Georgios Tsivgoulis and Apostolos Safouris and Anastasia Bougea and Sotiris Giannopoulos and Stergios Gatzonis and Nikolaos Triantafyllou",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.yebeh.2015.12.025",
language = "English (US)",
volume = "55",
pages = "84--86",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy

AU - Artemiadis, Artemios K.

AU - Lambrinoudaki, Irene

AU - Voskou, Panagiota

AU - Tsivgoulis, Georgios

AU - Safouris, Apostolos

AU - Bougea, Anastasia

AU - Giannopoulos, Sotiris

AU - Gatzonis, Stergios

AU - Triantafyllou, Nikolaos

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Enzyme-inducing antiepileptic drugs AEDs have adverse effects on bone mineral density (BMD), whereas studies on levetiracetam (LEV), a nonenzyme-inducing agent, have showed conflicting results. The aim of this study was to further elucidate the role of LEV in bone health. A sample of forty-six patients with epilepsy (mean age: 35.7 years, range: 20.2-64.2 years, 39.1% males) on LEV monotherapy for at least one year (range: 1.5-14.5 years, median 5.5 years) underwent femoral neck (FN) and lumbar spine (LS) BMD measurements. The T- and Z-scores were calculated. Results showed that 15.2% of the patients were identified with osteopenia and none with osteoporosis. Pearson's correlations revealed a negative but not significant association of LEV duration with bone-related measurements (range of rhos: from - 0.004 to - 0.23), except for LS T-scores. In terms of FN BMD measurements, Z-scores, and T-scores, longer LEV therapy duration had adverse but not significant effects on bone health after adjusting for age and gender. With regard to LS BMD measurements, Z-scores, and T-scores, men taking LEV for at least 5.5 years had better, although not significant, bone health compared with men with shorter LEV exposure, after adjusting for age. The opposite was found in women, although differences did not reach significance. These preliminary results are indicative of a differential effect of LEV therapy duration in men and women, which could presumably account for the incongruity of the already published studies. Also, LS assessments were more sensitive to these gender differences. Future larger studies should validate these results.

AB - Enzyme-inducing antiepileptic drugs AEDs have adverse effects on bone mineral density (BMD), whereas studies on levetiracetam (LEV), a nonenzyme-inducing agent, have showed conflicting results. The aim of this study was to further elucidate the role of LEV in bone health. A sample of forty-six patients with epilepsy (mean age: 35.7 years, range: 20.2-64.2 years, 39.1% males) on LEV monotherapy for at least one year (range: 1.5-14.5 years, median 5.5 years) underwent femoral neck (FN) and lumbar spine (LS) BMD measurements. The T- and Z-scores were calculated. Results showed that 15.2% of the patients were identified with osteopenia and none with osteoporosis. Pearson's correlations revealed a negative but not significant association of LEV duration with bone-related measurements (range of rhos: from - 0.004 to - 0.23), except for LS T-scores. In terms of FN BMD measurements, Z-scores, and T-scores, longer LEV therapy duration had adverse but not significant effects on bone health after adjusting for age and gender. With regard to LS BMD measurements, Z-scores, and T-scores, men taking LEV for at least 5.5 years had better, although not significant, bone health compared with men with shorter LEV exposure, after adjusting for age. The opposite was found in women, although differences did not reach significance. These preliminary results are indicative of a differential effect of LEV therapy duration in men and women, which could presumably account for the incongruity of the already published studies. Also, LS assessments were more sensitive to these gender differences. Future larger studies should validate these results.

UR - http://www.scopus.com/inward/record.url?scp=84953897349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953897349&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2015.12.025

DO - 10.1016/j.yebeh.2015.12.025

M3 - Article

VL - 55

SP - 84

EP - 86

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -